Literature DB >> 33784008

BCL2L2 loss renders -14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors.

Yinfeng Lyu1,2, Kunping Li1,2, Yuqing Li1,2, Hui Wen1,2, Chenchen Feng1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33784008      PMCID： PMC7933017          DOI： 10.1002/ctm2.348

Source DB:  PubMed          Journal:  Clin Transl Med        ISSN： 2001-1326


× No keyword cloud information.
  10 in total

1.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

2.  Association between copy-number alteration of +20q, -14q and -18p and cross-sensitivity to tyrosine kinase inhibitors in clear-cell renal cell carcinoma.

Authors:  Liang Wang; Yuqing Li; Yinfeng Lyu; Hui Wen; Chenchen Feng
Journal:  Cancer Cell Int       Date:  2020-10-06       Impact factor: 5.722

3.  Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.

Authors:  Nils Kroeger; Tobias Klatte; Karim Chamie; P Nagesh Rao; Frédéric D Birkhäuser; Geoffrey A Sonn; Joseph Riss; Fairooz F Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Journal:  Cancer       Date:  2013-01-18       Impact factor: 6.860

4.  Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.

Authors:  Elizabeth A Punnoose; Joel D Leverson; Franklin Peale; Erwin R Boghaert; Lisa D Belmont; Nguyen Tan; Amy Young; Michael Mitten; Ellen Ingalla; Walter C Darbonne; Anatol Oleksijew; Paul Tapang; Peng Yue; Jason Oeh; Leslie Lee; Sophie Maiga; Wayne J Fairbrother; Martine Amiot; Andrew J Souers; Deepak Sampath
Journal:  Mol Cancer Ther       Date:  2016-03-03       Impact factor: 6.261

5.  Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.

Authors:  Junfei Jin; Ying Xiong; Bo Cen
Journal:  Anticancer Drugs       Date:  2017-11       Impact factor: 2.248

6.  The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity.

Authors:  Daniel A R Heisey; Timothy L Lochmann; Konstantinos V Floros; Colin M Coon; Krista M Powell; Sheeba Jacob; Marissa L Calbert; Maninderjit S Ghotra; Giovanna T Stein; Yuki Kato Maves; Steven C Smith; Cyril H Benes; Joel D Leverson; Andrew J Souers; Sosipatros A Boikos; Anthony C Faber
Journal:  Clin Cancer Res       Date:  2018-10-22       Impact factor: 12.531

7.  Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer.

Authors:  Kyung Hwa Choi; Jeong Yong Jeon; Young-Eun Lee; Seung Won Kim; Sang Yong Kim; Yeo Jin Yun; Ki Cheong Park
Journal:  Transl Oncol       Date:  2018-12-03       Impact factor: 4.243

8.  HIF1α is not a target of 14q deletion in clear cell renal cancer.

Authors:  Niraj Shenoy
Journal:  Sci Rep       Date:  2020-10-19       Impact factor: 4.379

9.  Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation.

Authors:  Yuqing Li; Yanyun Shen; Zhidong Zhu; Hui Wen; Chenchen Feng
Journal:  Cancer Med       Date:  2020-07-06       Impact factor: 4.452

10.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.

Authors:  Wanjuan Yang; Jorge Soares; Patricia Greninger; Elena J Edelman; Howard Lightfoot; Simon Forbes; Nidhi Bindal; Dave Beare; James A Smith; I Richard Thompson; Sridhar Ramaswamy; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Cyril Benes; Ultan McDermott; Mathew J Garnett
Journal:  Nucleic Acids Res       Date:  2012-11-23       Impact factor: 16.971
  10 in total
  1 in total

1.  Arborinine from Glycosmis parva leaf extract inhibits clear-cell renal cell carcinoma by inhibiting KDM1A/UBE2O signaling.

Authors:  Chenchen Feng; Lingxiao Gong; Jing Wang
Journal:  Food Nutr Res       Date:  2022-09-16       Impact factor: 3.221
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.